Clinical Trial Finder

Comments

For metastatic MSS CRC patients with untreated liver mets, no surgical candidates.
Sintilimab: anti PD-1
In combination with Xelox (capecitabine+ oxaliplatin) + Avastin (bevacizumab)

Inclusion Criteria

Inclusion Criteria:

* Age ≥18 years old and ≤75 years old
* Histologically confirmed colorectal adenocarcinoma
* Radiologically and/or pathologically confirmed liver metastasis
* Immunohistochemistry and/or genetic testing confirmed pMMR/MSS
* Absence of extrahepatic metastasis confirmed by CT, MRI or PET/CT (if necessary)
* Primary lesion has been or can be removed by radical surgery
* Liver metastases can be resected (or using intraoperative radiofrequency) and is expected to achieve tumor-free status (NED) after surgery. Resectable liver metastases are defined explicitly as ① less than 5 metastatic lesions; ② R0 resection is achievable by resection or intraoperative radiofrequency; ③ Remaining liver volume is expected to be sufficient after surgery; ④ The following can be retained after resection: One hepatic vein, preserve blood flow in and out of the remaining liver, the bile duct, and at least 2 adjacent livers segments ⑤ There is no extrahepatic metastasis.
* Apart from surgical resection of the primary lesion, he/she has not received any anti-tumor treatment for liver metastasis (including chemotherapy, targeted drugs, interventional therapy, immunotherapy, radiotherapy, etc.)
* Normal hematological function (platelets>90×109/L; white blood cells>3×109/L; neutrophils>1.5×109/L)
* Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), transaminase ≤ 5 times ULN, alkaline phosphatase ≤2.5 ULN, No ascites, normal coagulation function, albumin ≥35g/L
* Child-Pugh classification of the liver is A
* Serum creatinine is less than the upper limit of normal (ULN), or the calculated creatinine clearance rate is greater than 50ml/min (using Cockcroft-Gault formula)
* ECOG score 0-1
* Life expectancy> 3 months
* Signed and written informed consent
* Willing and able to follow up until death or the end of the study or the study is terminated

Exclusion Criteria

Exclusion Criteria:

* Presence of distant metastases outside the liver after the diagnosis of colorectal cancer
* Liver metastases have been treated with chemotherapy, targeted drugs, intervention, immunotherapy, radiotherapy, etc.
* No surgical resection plan for liver metastases
* Received oxaliplatin-containing adjuvant chemotherapy in the past 1 year
* Any residual toxicity from previous chemotherapy (except for hair loss), such as peripheral neuropathy ≥NCI CTC v3.0 Grade 2
* Use of immunosuppressive drugs within 1 week before treatment, not including nasal sprays, inhalation or other local treatments, partial glucocorticoids or physiological doses of systemic glucocorticoids (i.e. not more than 10 mg/day prednisone or equivalent doses of other glucocorticoids) or use of corticoids to prevent contrast agent allergy
* Suffering from interstitial lung disease that requires steroid therapy
* Medical history of active autoimmune disease that needs symptomatic treatment within the past 2 years. Vitiligo, psoriasis, hair loss, or Grave's disease that do not require systemic treatment within the past 2 years, or hypothyroidism patients that only need thyroid hormone replacement therapy and type I diabetic patients requiring only insulin replacement therapy can be enrolled
* History of primary immunodeficiency
* Active tuberculosis
* Known history of allergies related to organ transplantation or hematopoietic stem cell transplantation
* Allergic to any monoclonal antibody or chemotherapeutic drug (fluorouracil, oxaliplatin) and its ingredients
* Have bleeding tendency or coagulopathy
* Patients with apparent symptoms of intestinal obstruction
* Hypertensive crisis or hypertensive encephalopathy
* Serious uncontrollable systemic complications such as infection or diabetes
* Clinically severe cardiovascular diseases such as cerebrovascular accident (within 6 months before enrollment), myocardial infarction (enrollment within the first 6 months), uncontrollable hypertension, unstable angina pectoris, heart failure (NYHA 2-4), arrhythmia requiring medical treatment
* Presence of central nervous system disease ( such as primary brain tumor, history of uncontrollable epilepsy, any brain metastases or stroke)
* Suffered from other malignant tumors in the past 5 years (except resected skin basal cell carcinoma and/or cervical carcinoma in situ)
* Received any drug treatment used for this study in the last 28 days
* Women who are pregnant and breastfeeding. Women of childbearing age who do not use or refuse to use effective non-hormonal contraceptive methods (intrauterine contraceptive ring, barrier contraception combined with spermicidal gel or female sterilization ) (<2 years after the last menstruation) or men with childbearing potential who are unable or unwilling to comply with the research protocol